Trial Profile
To Study the Pharmacokinetic Characteristics of TQ-B3233 in the Human Body, Recommend a Reasonable Regimen for Subsequent Research
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs TQ-B3233 (Primary)
- Indications Malignant melanoma; Tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 12 Mar 2018 New trial record